Literature DB >> 25917955

Association between lipid levels and major adverse cardiovascular events in rheumatoid arthritis compared to non-rheumatoid arthritis patients.

Katherine P Liao1, Jun Liu1, Bing Lu1, Daniel H Solomon1, Seoyoung C Kim1.   

Abstract

OBJECTIVE: Lower levels of low-density lipoprotein (LDL) cholesterol may be associated with increased cardiovascular (CV) risk in rheumatoid arthritis (RA). This study was undertaken to determine whether the complex relationship between levels of LDL and high-density lipoprotein (HDL) cholesterol and CV risk is different in RA patients as compared to non-RA controls.
METHODS: Using data from a US health insurance plan (2003-2012), we conducted a cohort study that included patients with RA and non-RA control subjects matched with regard to age, sex, and index date. The nonlinearity of associations between lipid levels and incidence of major adverse CV events (MACE) was tested. We used multivariable Cox proportional hazards regression models to examine for an interaction between lipid levels and RA status in relation to the risk of MACE, after adjustment for CV risk factors.
RESULTS: In total, 16,085 RA patients and 48,499 non-RA controls were studied. The mean age was 52.6 years and 78.6% were women. The relationship between LDL cholesterol levels and incidence of MACE was nonlinear and similar between RA patients and non-RA controls (P for interaction = 0.72). No significant increase in CV risk was observed between the lowest quintile of LDL cholesterol levels (≤91.0 mg/dl) and the second, third, or fourth quintiles, whereas the highest quintile (>190.0 mg/dl) conveyed a 40% increase in risk of MACE (hazard ratio [HR] 1.40, 95% confidence interval [95% CI] 1.17-1.68). The relationship between HDL cholesterol levels and incidence of MACE was also nonlinear and similar between RA patients and non-RA controls (P for interaction = 0.39). Compared to the lowest quintile of HDL cholesterol levels, each successive quintile was associated with a reduced risk of MACE (HR 0.45, 95% CI 0.48-0.72 for lowest quintile [≤43.0 mg/dl] versus highest quintile [>71.0 mg/dl]).
CONCLUSION: The complex relationship between LDL cholesterol levels, HDL cholesterol levels, and risk of MACE was nonlinear in RA patients and also not statistically significantly different from that in an age- and sex-matched non-RA cohort.
© 2015, American College of Rheumatology.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25917955      PMCID: PMC4418211          DOI: 10.1002/art.39165

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  33 in total

1.  High density lipoprotein cholesterol and mortality. The Framingham Heart Study.

Authors:  P W Wilson; R D Abbott; W P Castelli
Journal:  Arteriosclerosis       Date:  1988 Nov-Dec

2.  The association between inflammatory markers, serum lipids and the risk of cardiovascular events in patients with rheumatoid arthritis.

Authors:  Jie Zhang; Lang Chen; Elizabeth Delzell; Paul Muntner; William B Hillegass; Monika M Safford; Iris Yolanda Navarro Millan; Cynthia S Crowson; Jeffrey R Curtis
Journal:  Ann Rheum Dis       Date:  2014-05-05       Impact factor: 19.103

3.  Cardiovascular risk factors in women with and without rheumatoid arthritis.

Authors:  Daniel H Solomon; Gary C Curhan; Eric B Rimm; Carolyn C Cannuscio; Elizabeth W Karlson
Journal:  Arthritis Rheum       Date:  2004-11

4.  Total serum cholesterol levels and mortality risk as a function of age. A report based on the Framingham data.

Authors:  R A Kronmal; K C Cain; Z Ye; G S Omenn
Journal:  Arch Intern Med       Date:  1993-05-10

Review 5.  HDL-cholesterol as a marker of coronary heart disease risk: the Québec cardiovascular study.

Authors:  J P Després; I Lemieux; G R Dagenais; B Cantin; B Lamarche
Journal:  Atherosclerosis       Date:  2000-12       Impact factor: 5.162

6.  Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study.

Authors:  W P Castelli; R J Garrison; P W Wilson; R D Abbott; S Kalousdian; W B Kannel
Journal:  JAMA       Date:  1986-11-28       Impact factor: 56.272

7.  Dyslipoproteinemia in the course of active rheumatoid arthritis.

Authors:  M B Lazarevic; J Vitic; V Mladenovic; B L Myones; J L Skosey; W I Swedler
Journal:  Semin Arthritis Rheum       Date:  1992-12       Impact factor: 5.532

8.  Survival in rheumatoid arthritis: a population-based analysis of trends over 40 years.

Authors:  Sherine E Gabriel; Cynthia S Crowson; Hilal Maradit Kremers; Michele F Doran; Carl Turesson; W Michael O'Fallon; Eric L Matteson
Journal:  Arthritis Rheum       Date:  2003-01

9.  Accuracy of Medicare claims-based diagnosis of acute myocardial infarction: estimating positive predictive value on the basis of review of hospital records.

Authors:  Yuka Kiyota; Sebastian Schneeweiss; Robert J Glynn; Carolyn C Cannuscio; Jerry Avorn; Daniel H Solomon
Journal:  Am Heart J       Date:  2004-07       Impact factor: 4.749

10.  Effects of disease modifying agents and dietary intervention on insulin resistance and dyslipidemia in inflammatory arthritis: a pilot study.

Authors:  Patrick H Dessein; Barry I Joffe; Anne E Stanwix
Journal:  Arthritis Res       Date:  2002-09-16
View more
  24 in total

Review 1.  Cardiovascular and Metabolic Comorbidities in Rheumatoid Arthritis.

Authors:  Silvio Romano; Elisa Salustri; Piero Ruscitti; Francesco Carubbi; Maria Penco; Roberto Giacomelli
Journal:  Curr Rheumatol Rep       Date:  2018-11-05       Impact factor: 4.592

2.  Disease Activity, Antineutrophil Cytoplasmic Antibody Type, and Lipid Levels in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Zachary S Wallace; Xiaoqing Fu; Katherine Liao; Cees G M Kallenberg; Carol A Langford; Peter A Merkel; Paul Monach; Philip Seo; Ulrich Specks; Robert Spiera; E William St Clair; Yuqing Zhang; Hyon Choi; John H Stone
Journal:  Arthritis Rheumatol       Date:  2019-09-16       Impact factor: 10.995

3.  Exploring the Lipid Paradox Theory in Rheumatoid Arthritis: Associations of Low Circulating Low-Density Lipoprotein Concentration With Subclinical Coronary Atherosclerosis.

Authors:  Jon T Giles; Mary Chester M Wasko; Cecilia P Chung; Moyses Szklo; Roger S Blumenthal; Amy Kao; Sabahat Bokhari; Afshin Zartoshti; C Michael Stein; Joan M Bathon
Journal:  Arthritis Rheumatol       Date:  2019-08-01       Impact factor: 10.995

Review 4.  Atherosclerotic cardiovascular disease prevention in rheumatoid arthritis.

Authors:  Anne Grete Semb; Eirik Ikdahl; Grunde Wibetoe; Cynthia Crowson; Silvia Rollefstad
Journal:  Nat Rev Rheumatol       Date:  2020-06-03       Impact factor: 20.543

5.  [Treatment of cardiovascular risk factors].

Authors:  K Krüger
Journal:  Z Rheumatol       Date:  2016-03       Impact factor: 1.372

6.  Heart failure risk in systemic lupus erythematosus compared to diabetes mellitus and general medicaid patients.

Authors:  Sarah K Chen; Medha Barbhaiya; Michael A Fischer; Hongshu Guan; Kazuki Yoshida; Candace H Feldman; Karen H Costenbader; Brendan M Everett
Journal:  Semin Arthritis Rheum       Date:  2019-06-11       Impact factor: 5.532

Review 7.  Lipids in RA: Is Less Not Necessarily More?

Authors:  Jorge Plutzky; Katherine P Liao
Journal:  Curr Rheumatol Rep       Date:  2018-02-21       Impact factor: 4.592

8.  Impact of risk factors associated with cardiovascular outcomes in patients with rheumatoid arthritis.

Authors:  Cynthia S Crowson; Silvia Rollefstad; Eirik Ikdahl; George D Kitas; Piet L C M van Riel; Sherine E Gabriel; Eric L Matteson; Tore K Kvien; Karen Douglas; Aamer Sandoo; Elke Arts; Solveig Wållberg-Jonsson; Lena Innala; George Karpouzas; Patrick H Dessein; Linda Tsang; Hani El-Gabalawy; Carol Hitchon; Virginia Pascual Ramos; Irazú Contreras Yáñez; Petros P Sfikakis; Evangelia Zampeli; Miguel A Gonzalez-Gay; Alfonso Corrales; Mart van de Laar; Harald E Vonkeman; Inger Meek; Anne Grete Semb
Journal:  Ann Rheum Dis       Date:  2017-09-06       Impact factor: 19.103

Review 9.  Cardiac Impairment in Rheumatoid Arthritis and Influence of Anti-TNFα Treatment.

Authors:  Ivica Lazúrová; Ľubomír Tomáš
Journal:  Clin Rev Allergy Immunol       Date:  2017-06       Impact factor: 8.667

10.  Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis.

Authors:  Alexis Ogdie; Lihi Eder
Journal:  Int J Clin Rheumtol       Date:  2015-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.